|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2023-02-28 |
靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
/ Not yet recruiting早期临床1期 An Exploratory Study of Personalized Neoantigen MRNA Vaccine RGL-270 Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients
This is a phase IIT , it is an open-label study designed to evaluate the safety and tolerability of personalized mRNA tumor vaccine RGL-270 targeting tumor-specific neoantigens and Adebrelimab (a humanized PD-L1 monoclonal antibody) in patients with resectable NSCLC and those with NSCLC who have relapsed or metastasized after first-line standard therapy.
100 项与 南京天印山医院有限公司 相关的临床结果
0 项与 南京天印山医院有限公司 相关的专利(医药)
100 项与 南京天印山医院有限公司 相关的药物交易
100 项与 南京天印山医院有限公司 相关的转化医学